Mundipharma acquires European rights to biosimilar Herzuma for breast cancer and gastric cancer.- Celltrion.
The Mundipharma global network of independent associated companies strengthened its partnership with biopharmaceutical company Celltrion Healthcare Hungary Kft, by securing exclusive distribution rights to its trastuzumab biosimilar, Herzuma in seven EU markets including Germany, Italy and the UK. Herzuma, which is a biosimilar of the reference biologic i.v. Herceptin , was granted marketing authorisation on 9th February 2018 following positive opinion and recommendation for approval by the European Medicines Agency�s (EMA) Committee for Medicinal Products for Human Use (CHMP) in December 2017 for HER2-positive early breast cancer in the neo-adjuvant and adjuvant setting, metastatic breast cancer, and metastatic gastric cancer in adults.
Breast cancer remains the most prevalent form of cancer in women in Europe, affecting an estimated 362,000 women and causing around 92,000 deaths in 2012, with a five-year prevalence of over 1.4 million. 15�20% of primary breast cancers are HER2-positive, which can be more aggressive than other types of breast cancer.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins